Phio Pharmaceuticals Announces Patent Granted By USPTO, Strengthening The Company's Intellectual Property Position In Treating Aging Skin And Skin Disorders
Portfolio Pulse from Benzinga Newsdesk
Phio Pharmaceuticals Corp. (NASDAQ:PHIO) announced the USPTO granted a patent for two INTASYL Compounds, RXI-185 and RXI-231, targeting aging skin and skin disorders. This strengthens Phio's intellectual property, with the portfolio now including 81 issued patents, 77 of which cover the INTASYL siRNA gene silencing technology. The compounds aim to treat conditions like photo-aging and dermal hyperpigmentation by silencing specific proteins, potentially improving skin conditions.
March 06, 2024 | 3:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Phio Pharmaceuticals Corp. announced a significant enhancement to its intellectual property with a new patent grant from the USPTO for compounds RXI-185 and RXI-231, aimed at treating aging skin and skin disorders.
The granting of a new patent by the USPTO for Phio Pharmaceuticals' compounds RXI-185 and RXI-231 is likely to have a positive short-term impact on PHIO's stock price. This development not only strengthens the company's intellectual property portfolio but also highlights its ongoing efforts and potential in addressing skin-related conditions through its INTASYL technology. The news could increase investor confidence in Phio's innovative capabilities and its future market potential, thereby potentially driving up the stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100